Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription


1 Am J Respir Crit Care Med
2 Arch Bronconeumol
4 BMC Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
4 Cancer Sci
3 Chest
2 Clin Exp Metastasis
1 Clin Lung Cancer
1 Clin Nucl Med
3 Eur J Cardiothorac Surg
1 Eur Respir J
1 Int J Cancer
1 J Natl Cancer Inst
4 Lung Cancer
1 Mol Carcinog
2 Oncologist
1 Thorax

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Respir Crit Care Med

  1. WANG S, Meng F, Li M, Bao H, et al
    Multi-Dimensional Cell-free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
    Am J Respir Crit Care Med. 2022 Nov 8. doi: 10.1164/rccm.202109-2019.
    PubMed         Abstract available

    Arch Bronconeumol

  2. PEREIRA BARROS P, Dos Santos B, Brito U
    Lung Cancer With Cold Agglutinin Syndrome as a Paraneoplastic Syndrome: A Case Report.
    Arch Bronconeumol. 2022 Oct 20. pii: S0300-2896(22)00591.

  3. GONZALEZ GARCIA JA, Rodriguez Alvarado EI, Gutierrez Ramirez MC
    Magnetic-Guided Occult Lesion Localization (M-GOLL): An Innocuous and Efficient Technique for Assisting Surgical Resection of Pulmonary Nodules.
    Arch Bronconeumol. 2022;58:766-767.

    BMC Cancer

  4. ASAO T, Watanabe S, Tanaka T, Morita S, et al
    A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    BMC Cancer. 2022;22:1135.
    PubMed         Abstract available

  5. PAN J, Huang Z, Lin H, Cheng W, et al
    M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
    BMC Cancer. 2022;22:1132.
    PubMed         Abstract available

  6. JIANG L, Sun YQ, Brumpton BM, Langhammer A, et al
    Body mass index and incidence of lung cancer in the HUNT study: using observational and Mendelian randomization approaches.
    BMC Cancer. 2022;22:1152.
    PubMed         Abstract available

  7. SATO K, Akamatsu H, Koh Y, Ogawa K, et al
    Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
    BMC Cancer. 2022;22:1148.
    PubMed         Abstract available


    Lung cancer: Radiographers reporting x rays halves time to diagnosis, study finds.
    BMJ. 2022;379:o2684.

    Cancer Chemother Pharmacol

  9. KITANO S, Fujiwara Y, Shimizu T, Iwasa S, et al
    A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
    Cancer Chemother Pharmacol. 2022;90:523-529.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  10. CIGAN SS, Murphy SE, Stram DO, Hecht SS, et al
    Association of urinary biomarkers of smoking-related toxicants with lung cancer incidence in smokers: The Multiethnic Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2022 Nov 9. pii: 710531.
    PubMed         Abstract available

    Cancer Sci

  11. HUANG Y, Zheng Y, Yao L, Qiao F, et al
    RNA binding protein POP7 regulates ILF3 mRNA stability and expression to promote breast cancer progression.
    Cancer Sci. 2022;113:3801-3813.
    PubMed         Abstract available

  12. NISHIO S, Yonemori K, Usami T, Minobe S, et al
    Pembrolizumab Plus Chemotherapy in Japanese Patients With Persistent, Recurrent or Metastatic Cervical Cancer: Results From KEYNOTE-826.
    Cancer Sci. 2022 Jul 6. doi: 10.1111/cas.15479.
    PubMed         Abstract available

  13. OCHIAI R, Hayashi K, Yamamoto H, Fujii R, et al
    Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment.
    Cancer Sci. 2022;113:3960-3971.
    PubMed         Abstract available

  14. ZHU Y, Yang Y, Bu H, Huang H, et al
    Apelin-mediated deamidation of HMGA1 promotes tumorigenesis by enhancing SREBP1 activity and lipid synthesis.
    Cancer Sci. 2022;113:3722-3734.
    PubMed         Abstract available


  15. URUGA H, Mino-Kenudson M
    Preoperative Biopsy Does Not Generate STAS?
    Chest. 2022;162:963-964.

    Welcome to the Real World: Understanding the Many Faces of Osimertinib-Related Pneumonitis.
    Chest. 2022;162:965-967.

  17. SALUJA P, Patel V, Gautam N, Caceres JD, et al
    A 72-Year-Old Woman With Dyspnea, Multiple Pulmonary Nodules, and Mediastinal Lymphadenopathy.
    Chest. 2022;162:e253-e257.
    PubMed         Abstract available

    Clin Exp Metastasis

  18. ORBACH SM, Brooks MD, Zhang Y, Campit SE, et al
    Single-cell RNA-sequencing identifies anti-cancer immune phenotypes in the early lung metastatic niche during breast cancer.
    Clin Exp Metastasis. 2022 Aug 24. pii: 10.1007/s10585-022-10185.
    PubMed         Abstract available

  19. MARAYATI R, Julson J, Bownes LV, Quinn CH, et al
    PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
    Clin Exp Metastasis. 2022;39:899-912.
    PubMed         Abstract available

    Clin Lung Cancer

  20. LI A, Chen HJ, Yang JJ
    Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Tri
    Clin Lung Cancer. 2022 Sep 30. pii: S1525-7304(22)00205.
    PubMed         Abstract available

    Clin Nucl Med

  21. TRAK J, Hasanovic A, Gavane S
    18F-FDG and 18F-Fluciclovine Uptake in Poorly Differentiated Lung Adenocarcinoma in the Setting of Biochemically Recurrent Prostatic Adenocarcinoma.
    Clin Nucl Med. 2022;47:1077-1078.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  22. GOMEZ-HERNANDEZ MT, Forcada C, Varela G, Jimenez MF, et al
    Operating time: an independent and modifiable risk factor for short-term complications after video-thoracoscopic pulmonary lobectomy.
    Eur J Cardiothorac Surg. 2022;62.
    PubMed         Abstract available

  23. GONZALEZ M, Chriqui LE, Decaluwe H, Aigner C, et al
    Sleeve lobectomy in patients with non-small-cell lung cancer: a report from the European Society of Thoracic Surgery database 2021.
    Eur J Cardiothorac Surg. 2022;62.
    PubMed         Abstract available

  24. HAIDARI TA, Bjerrum F, Grimstrup S, Christensen TD, et al
    The left upper lobe challenge in video-assisted thoracoscopic surgery-use of a composite score to improve the assessment of simulated lobectomy.
    Eur J Cardiothorac Surg. 2022;62.
    PubMed         Abstract available

    Eur Respir J

  25. MAGENHEIM J, Rokach A, Peretz A, Loyfer N, et al
    Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies.
    Eur Respir J. 2022;60.
    PubMed         Abstract available

    Int J Cancer

  26. YU Y, Chen K, Fan Y
    Extensive-Stage Small-Cell Lung Cancer: Current Management and Future Directions.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34346.
    PubMed         Abstract available

    J Natl Cancer Inst

  27. LI M, Liao K, Chen AJ, Cascone T, et al
    Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
    J Natl Cancer Inst. 2022 Nov 8. pii: 6809139. doi: 10.1093.
    PubMed         Abstract available

    Lung Cancer

  28. PINHEIRO PS, Callahan KE, Medina HN, Koru-Sengul T, et al
    Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race/ethnicity.
    Lung Cancer. 2022;174:50-56.
    PubMed         Abstract available

  29. TAN KS, Hsu M, Adusumilli PS
    Pathologic node-negative lung cancer: Adequacy of lymph node yield and a tool to assess the risk of occult nodal disease.
    Lung Cancer. 2022;174:60-66.
    PubMed         Abstract available

  30. CHAN JSK, Tang P, Ng K, Dee EC, et al
    Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study.
    Lung Cancer. 2022;174:67-70.
    PubMed         Abstract available

  31. ISOMOTO K, Haratani K, Tsujikawa T, Makutani Y, et al
    Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Lung Cancer. 2022;174:71-82.
    PubMed         Abstract available

    Mol Carcinog

  32. ZHANG Z, Chen Q, Huang C, Rao D, et al
    Transcription factor Nrf2 binds to circRNAPIBF1 to regulate SOD2 in lung adenocarcinoma progression.
    Mol Carcinog. 2022;61:1161-1176.
    PubMed         Abstract available


  33. CHIHARA Y, Takeda T, Goto Y, Nakamura Y, et al
    A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
    Oncologist. 2022;27:903-e834.
    PubMed         Abstract available

  34. YAO J, Bergsland E, Aggarwal R, Aparicio A, et al
    DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    Oncologist. 2022;27:940-951.
    PubMed         Abstract available


  35. WOZNITZA N, Ghimire B, Devaraj A, Janes SM, et al
    Impact of radiographer immediate reporting of X-rays of the chest from general practice on the lung cancer pathway (radioX): a randomised controlled trial.
    Thorax. 2022 Nov 8. pii: thorax-2022-219210. doi: 10.1136/thorax-2022-219210.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.